GW 678248

Known as: GW-678248, GW678248 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2005-2016
01220052016

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Through a structure-based molecular hybridization and bioisosterism approach, a series of novel 2-(pyridin-3-yloxy)acetamide… (More)
Is this relevant?
2016
2016
BACKGROUND Although a number of agents can achieve high response in acquired immunodeficiency syndrome (AIDS) patients, safer and… (More)
Is this relevant?
2012
2012
A series of N-phenylarylformamide derivatives (PAFAs) with anti-wild-type HIV-1 activity (EC(50) values) ranging from 0.3 nM to 5… (More)
Is this relevant?
2010
2010
Current antiretroviral therapy against human immunodeficiency virus (HIV-1) reduces viral load and thereby prevents viral spread… (More)
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • figure 4
Is this relevant?
2010
2010
GW695634 is the prodrug of GW678248, a novel non-nucleoside reverse transcriptase inhibitor with potent antiviral activity… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
2008
2008
Owing to the emergence of resistant virus, next generation non-nucleoside HIV reverse transcriptase inhibitors (NNRTIs) with… (More)
Is this relevant?
2006
2006
Despite the progress of the past two decades, there is still considerable need for safe, efficacious drugs that target human… (More)
Is this relevant?
2005
2005
The compound GW678248 is a novel benzophenone nonnucleoside reverse transcriptase inhibitor (NNRTI). Preclinical assessment of… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
2005
2005
GW678248, a novel nonnucleoside reverse transcriptase inhibitor, has been evaluated for anti-human immunodeficiency virus… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
Is this relevant?